The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 12, 2021

Filed:

Mar. 10, 2015
Applicant:

Molecular Templates, Inc., Austin, TX (US);

Inventors:

Eric Poma, New York, NY (US);

Jason Kim, Austin, TX (US);

Jack Higgins, Georgetown, TX (US);

Erin Willert, Round Rock, TX (US);

Sangeetha Rajagopalan, Round Rock, TX (US);

Assignee:

Molecular Templates, Inc., Austin, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 14/25 (2006.01); G01N 33/68 (2006.01); A61K 39/12 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2887 (2013.01); A61K 39/12 (2013.01); A61K 47/6829 (2017.08); A61K 47/6849 (2017.08); C07K 14/25 (2013.01); G01N 33/6872 (2013.01); A61K 2039/505 (2013.01); A61K 2039/6056 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2319/22 (2013.01); C07K 2319/30 (2013.01); C07K 2319/55 (2013.01); C12N 2760/16134 (2013.01); G01N 33/57426 (2013.01); G01N 2333/70596 (2013.01);
Abstract

The present invention provides CD20-binding proteins that bind to and rapidly internalize in a CD20-mediated fashion from a cell surface location to the interior of the cell. CD20-binding proteins of the invention comprise a CD20 binding region and a Shiga toxin effector region. Certain of the disclosed CD20-binding proteins kill cells that express CD20 on their surface. Further, the presently disclosed CD20-binding proteins can comprise additional exogenous materials, such as, e.g., antigens, and are capable of targeted delivery of these additional exogenous materials into the interior of CD20 expressing cells. These CD20-binding proteins have uses in methods such as, e.g., methods involving the efficient cellular internalization of CD20, targeted killing of CD20 expressing cells, delivering exogenous materials inside CD20 expressing cells, detecting CD20 expressing cells, and treating a variety of conditions involving CD20 expressing cells including cancers, tumors, growth abnormalities, and immune disorders.


Find Patent Forward Citations

Loading…